Sep 21 2009
Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that it had completed the previously announced sale of its Sleep Diagnostics assets to Embla Systems. Financial terms of the transaction were not disclosed.
The sale of the Sleep Diagnostics product line, which includes several products sold under the Sandman™ brand, was made following a thorough review and evaluation of a number of strategic alternatives. The decision is consistent with Covidien’s strategy to streamline its portfolio and reallocate resources to its faster-growing, higher-margin businesses, where the Company has or can develop a global competitive advantage.
http://www.covidien.com/covidien/pageBuilder.aspx?page=Home:Home&topicID=161206